CHB


China Biotech Innovation ETF

Fund Summary

The Global X China Biotech Innovation ETF (CHB) seeks to invest in companies that are directly involved in China’s biotechnology industry.

Fund Objective

The Global X China Biotech Innovation ETF (CHB) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive China Biotech Innovation Index.

Why CHB?

High Growth Potential

CHB enables investors to access high growth potential through companies central to the development of biotechnology in China.

Targeted Exposure

CHB delivers targeted exposure to an emerging theme and industry.

ETF Efficiency

In a single trade, CHB delivers access to dozens of companies with high exposure to the biotech theme in China.

Fund Details As of 07/23/21

Key Facts

Ticker CHB
Inception Date 09/22/20
CUSIP 37954Y251
ISIN US37954Y2515
Bloomberg Index Ticker SOLCHB
Primary Exchange Nasdaq
Number of Holdings 34

Stats & Fees

Net Assets $6,285,059
Net Asset Value (NAV) $17.96
Shares Outstanding 350,000
Total Expense Ratio 0.67%

Distributions

30-Day SEC Yield N/A
Distribution Frequency Semi-Annually

Fund Prices As of 07/23/21

NAV $17.96 Daily Change -$0.54 -2.93%
Market Price $17.87 Daily Change -$0.68 -3.67%
30-Day Median Bid-Ask Spread 0.64%

Performance History

As of recent month & quarter-end (06/30/21)
Fund NAV Market Price Index
Year-to-Date 14.45% 14.79% 14.79%
1 Month -1.37% -1.47% -1.36%
3 Months 15.87% 15.71% 16.10%
Since Inception 23.86% 24.45% 24.47%
Year-to-Date 14.45% 14.79% 14.79%
1 Month -1.37% -1.47% -1.36%
3 Months 15.87% 15.71% 16.10%
Since Inception 23.86% 24.45% 24.47%

Cumulative return is the aggregate amount that an investment has gained or lost over time. Annualized return is the average return gained or lost by an investment each year over a given time period.

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. High short-term performance of the Fund, when observed, is unusual and investors should not expect such performance to be repeated.

Fund Characteristics As of 07/23/21

Return on Equity 5.80%
Weighted Avg. Market Cap 7,503 M
2020 2021
Price-to-earnings -2,028.51 116.17
Price-to-book value 6.88 6.68

Source: AltaVista Research, LLC

Top Holdings As of 07/23/21

Net Assets (%) Ticker Name SEDOL Market Price ($) Shares Held Market Value ($)
10.64 300142 C2 WALVAX BIOTECHNOLOGY CO-A BD5CG36 11.79 56,700 668,750.63
10.08 2269 HK WUXI BIOLOGICS CAYMAN INC BL6B9P1 16.69 37,950 633,546.14
7.72 BGNE BEIGENE LTD-ADR BYYWPW6 316.93 1,531 485,219.83
6.66 300601 C2 SHENZHEN KANGT-A BFY8HT2 20.35 20,571 418,648.02
6.26 000661 C2 CHANGCHUN HIGH-A BD5CDB3 56.39 6,974 393,297.88
4.42 300357 C2 ZHEJIANG WOLWO-A BFY8GY0 10.24 27,100 277,557.68
4.28 1548 HK GENSCRIPT BIOTECH CORP BD9Q2J2 4.68 57,550 269,262.73
4.10 002007 C2 HUALAN BIOLOGI-A BD5CL19 5.88 43,800 257,422.62
4.09 ZLAB ZAI LAB LTD-ADR BD9GVY0 150.00 1,713 256,950.00
4.01 1177 HK SINO BIOPHARMACEUTICAL B00XSF9 0.90 279,900 251,829.48
3.72 300676 C2 BGI GENOMICS CO LTD-A BFY8H58 15.44 15,138 233,743.30
3.34 600161 C1 BEIJING TIAN-A BP3R9J4 6.36 33,057 210,134.07
3.30 300009 C2 ANHUI ANKE BIO-A BD5C829 2.38 87,080 207,427.63
2.89 300725 C2 PHARMABLOCK SC-A BFY8HC5 22.17 8,181 181,378.16
2.66 603345 C1 FU JIAN ANJOY-A BMXWM11 26.52 6,300 167,075.96
2.40 002252 C2 SHANGHAI RAAS -A BD5CPJ5 1.15 130,600 150,815.06
2.40 603392 C1 BEIJING WANTAI-A BMXTWX4 40.24 3,740 150,498.38
2.06 002030 C2 DAAN GENE CO LTD-A BD5CKW3 2.83 45,780 129,377.26
2.01 603127 C1 JOINN LABORATO-A BK94819 27.48 4,600 126,389.10
2.01 002422 C2 SICHUAN KELUN-A BD5CL08 2.87 44,000 126,178.49
1.27 9939 HK KINTOR PHARMACEUTICAL LTD BMDWVN6 10.09 7,900 79,720.43
1.25 9966 HK ALPHAMAB ONCOLOGY BL6WGG4 3.41 23,000 78,451.31
1.25 1530 HK 3SBIO INC BY9D3L9 1.01 77,600 78,307.67
1.09 300639 C2 GUANGDONG HYBR-A BMQBTJ2 4.36 15,642 68,225.22
0.80 6855 HK ASCENTAGE PHARMA BK9PZW2 6.69 7,500 50,198.54
0.80 1873 HK VIVA BIOTECH HOLDINGS BJBL0L5 1.07 46,900 50,104.58
0.71 002038 C2 BEIJING SL -A BD5CJD7 1.51 29,600 44,678.04
0.66 000710 C2 BERRY GENOMICS CO LTD-A BFFJRH2 4.18 9,855 41,236.92
0.63 688366 C1 SHANGHAI HAOHA-A BLCD7D5 35.90 1,106 39,710.65
0.59 000078 C2 SHENZ NEPTUNUS-A BD5CBK8 0.49 75,700 37,231.13
0.51 2126 HK JW CAYMAN THERAP BN4NLR9 2.92 11,000 32,069.15
0.47 603387 C1 GETEIN BIOTECH INC-A BFB4S90 3.18 9,240 29,360.92
0.36 002880 C2 SHENZHEN WEIGU-A BMTCVX0 5.74 3,880 22,283.21
0.32 603363 C1 FUJIAN AONONG-A BF2DZF1 1.29 15,820 20,341.93
0.28 CASH 0.31 57,012 17,636.48
Holdings are subject to change.


Investing involves risk, including the possible loss of principal. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles, or from economic or political instability in other nations. Emerging markets involve heightened risks related to the same factors as well as increased volatility and lower trading volume. Investments in securities in the Biotechnology and Health Care sectors can be affected by government regulations, rapid product obsolescence, intense industry competition and loss or impairment of patents or intellectual property rights. Securities focusing on a single country and narrowly focused investments may be subject to higher volatility. CHB is non-diversified.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Beginning October 15, 2020, market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share. Prior to October 15, 2020, market price returns were based on the midpoint between the Bid and Ask price. NAVs are calculated using prices as of 4:00 PM Eastern Time. The returns shown do not represent the returns you would receive if you traded shares at other times. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Since the Fund’s shares typically do not trade in the secondary market until several days after the Fund’s inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.

Carefully consider the Fund’s investment objectives, risks, and charges and expenses before investing. This and other information can be found in the Fund’s summary or full prospectuses. Please read the prospectus carefully before investing.

Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive AG, nor does Solactive AG make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with Solactive AG.